SCHEMBL6285345

SCHEMBL6285345

N=C(N)c1cccc(NC(=O)Nc2ccc(S(=O)(=O)NCc3c(F)ccc(F)c3F)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 10/20 0.47
TMPRSS6 Q8IU80 4/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
ALOX15 P16050 2/20 0.45
MAPK1 P28482 2/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
GAA P10253 1/20 0.45
RAB9A P51151 1/20 0.45
PLAU P00749 2/20 0.44
TSHR P16473 1/20 0.44
HPN P05981 1/20 0.44
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281210 0.89 LMNA (0.49) MEN1KMT2ALMNAMAPTALOX15
SCHEMBL6280117 0.83 MEN1 (0.60) F2TMPRSS6MEN1KMT2AMAPT
SCHEMBL2762018 0.81 MEN1 (0.54) MEN1KMT2ALMNAMAPTALOX15
SCHEMBL6276930 0.81 CA2 (0.53) MEN1KMT2AMAPTTP53TSHR
SCHEMBL2762224 0.79 PLAU (0.55) F2TMPRSS6MEN1KMT2ALMNA
SCHEMBL2762122 0.79 HTR1A (0.41) MEN1KMT2ALMNAMAPTALOX15
SCHEMBL6280114 0.79 NAMPT (0.62) F2TMPRSS6MEN1KMT2ALMNA
SCHEMBL6286589 0.76 F2 (0.53) F2TMPRSS6MEN1KMT2ALMNA
SCHEMBL6276427 0.73 GPR55 (0.56) F2TMPRSS6MEN1KMT2AMAPT
SCHEMBL13791589 0.73 PLAU (0.71) F2TMPRSS6MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949567-B2 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2005-09-27 US disclosed
EP-1395548-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2004-03-10 EP disclosed
US-20030119876-A1 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2003-06-26 US disclosed
US-20020165236-A1 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2002-11-07 US disclosed
WO-2002070467-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165236-A1 Compounds for the treatment of protozoal diseases PKD2, PPOX, PKD1 F2 2898/4885TMPRSS6 502/4885MEN1 2642/4885
US-20030119876-A1 Compounds for the treatment of protozoal diseases CLIC1, PKD2, PKD1 F2 3408/4885TMPRSS6 2436/4885MEN1 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.